Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Indumathy Varadarajan"'
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1246-1251 (2024)
Introduction: Purpura fulminans is a rare but fatal manifestation of Capnocytophaga canimorsus bacteremia that can present in immunocompromised hosts. This can have a profound impact on patients, including recipients of allogeneic hematopoietic stem
Externí odkaz:
https://doaj.org/article/ea37226c41a4482cbeef5d3306ca6249
Autor:
Indumathy Varadarajan, Karen Ballen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is c
Externí odkaz:
https://doaj.org/article/222afd0b44024845b93112980783e446
Autor:
Indumathy Varadarajan, Aparna Basu, Sherri Besmer, Jaganmohan Poli, Scott Richard, Michael Styler
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 2, Pp 694-698 (2017)
Cervical cancer is the fourth most common cancer in women worldwide, with a large majority of prevalence (85%) in developing countries. As of 2012, it accounts for 7.5% of all female cancer deaths. Despite its high prevalence, skeletal muscle metasta
Externí odkaz:
https://doaj.org/article/3e1722b517444ee2bdd39158ed4272da
Publikováno v:
OncoTargets and Therapy. 16:1-16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed13d471058bed7ccfd7af69ed0bf669
https://doi.org/10.2147/ott.s274551
https://doi.org/10.2147/ott.s274551
Autor:
Nicholas P Lucchesi, Philip Young, Ravdeep Mathone, Leonid Volodin, Karen K Ballen, Indumathy Varadarajan
Publikováno v:
Transplantation and Cellular Therapy. 29:S143
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c216228946a6d7033d52334d6f70d24
https://doi.org/10.1016/s2666-6367(23)00248-8
https://doi.org/10.1016/s2666-6367(23)00248-8
Autor:
Indumathy Varadarajan, Bethany Horton, Leonid Volodin, Tamila Kindwall-Keller, Karen K Ballen
Publikováno v:
Transplantation and Cellular Therapy. 28:S158-S159
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b10b3c72139cf928425df52d6c02c9e3
https://doi.org/10.1016/s2666-6367(22)00355-4
https://doi.org/10.1016/s2666-6367(22)00355-4
Autor:
Indumathy Varadarajan, Shambhavi Singh, Ioannis Vassalos, Leonid Volodin, Tamila Kindwall-Keller, Karen K Ballen
Publikováno v:
Transplantation and Cellular Therapy. 28:S269-S270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5ed89515b7424f6d27c36a16df851d8
https://doi.org/10.1016/s2666-6367(22)00508-5
https://doi.org/10.1016/s2666-6367(22)00508-5
Autor:
Daniel R. Reed, Gina R. Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G. Williams, Kathlene DeGregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan, Leonid Volodin, Gerald R. Donowitz, Tamila L. Kindwall-Keller, Karen K. Ballen
Publikováno v:
Hematology/Oncology and Stem Cell Therapy.
Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60-70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c167da54e1f01192c9b0bd95e513a82d
https://doi.org/10.1016/j.hemonc.2021.05.001
https://doi.org/10.1016/j.hemonc.2021.05.001
Autor:
Indumathy Varadarajan, Daniel W. Lee
Publikováno v:
The Cancer Journal. 25:223-230
The advent of T-cell-mediated immunotherapy has led to a new era in the treatment of relapsed, refractory B-cell lymphomas and leukemias. Chimeric antigen receptor T-cell and engineered T-cell receptor therapies have demonstrated impressive efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3ea8521f3c7fc58dde82530f590230
https://doi.org/10.1097/ppo.0000000000000377
https://doi.org/10.1097/ppo.0000000000000377
Cytokine release syndrome (CRS) is the most frequently occurring toxicity in patients treated with chimeric antigen receptor T-cell therapies. The definition and grading of CRS has varied over the years. Only recently has the community come to consen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::700eed2d3c117120e9f35a7bf8216bd1
https://doi.org/10.1016/b978-0-323-66181-2.00005-6
https://doi.org/10.1016/b978-0-323-66181-2.00005-6
